About Us

About GeneAssess

GeneAssess, Inc. is an early stage biotech company, founded in 2012. The company maintains office space at 120 Albany Street, New Brunswick, NJ 08901. Our current focus is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for cancer patients.

We are developing new diagnostic and genetic tests for assessing cancer risk based on the expression and the DNA sequence of the FRY, a putative tumor suppressor gene and a novel cancer biomarker. In addition, we intend to develop mechanistically-based, percision cancer therapies using FRY signal targeting methodology. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY.

Value Proposition

GeneAssess will develop unique, proprietary tests for cancer progression and genetic risk, initially for breast cancer. However, research indicates that FRY expression is associated with the progression and poor outcomes of many other cancers, indicating that the tests may be applicable to all major cancer types. FRY based tests could become part of the standard diagnostic battery for a majority of cancer patients. Thus, any mechanistically-based therapies developed to target FRY signaling pathways would also be applicable to a wide variety of carcinomas.